MLYS Stock Price
Mineralys Therapeutics, Inc.
MLYS stock price is $21.64 (+4.24% on the day), giving Mineralys Therapeutics, Inc. a market cap of $1.84B. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
MLYS Stock Overview
- Price
- $21.64
- Previous close
- $20.76
- Open
- $21.04
- Market cap
- $1.84B
- P/E ratio
- -11.9
- 52-week range
- $21.46 - $47.65
- 1-year price target
- $48.50
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 36
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MLYS | $21.64 | +4.2% | 1.09M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Mineralys Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW